Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS6105-TPS6105
Author(s):  
Christophe Le Tourneau ◽  
Jean-Pierre Delord ◽  
Gilles Dolivet ◽  
Olivier Capitain ◽  
Laurent Laccourreye ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Neck Squamous Cell Carcinoma ◽  
Randomized Phase Ii ◽  
Pharmacodynamic Biomarkers

scholarly journals A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

2021 ◽  
Author(s):  
Ji Hyun Lee ◽  
Seong Gu Heo ◽  
Beung‐Chul Ahn ◽  
Min Hee Hong ◽  
Byoung Chul Cho ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Neck Squamous Cell Carcinoma

scholarly journals A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

2014 ◽  
Vol 25 (9) ◽  
pp. 1813-1820 ◽  
Author(s):  
T.Y. Seiwert ◽  
J. Fayette ◽  
D. Cupissol ◽  
J.M. del Campo ◽  
P.M. Clement ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Study ◽  
Randomized Phase Ii ◽  
Recurrent Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document